XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2025
Segment Information  
Schedule of research and development costs

Three Months Ended

Three Months Ended

Nine Months Ended

Nine Months Ended

    

September 30, 2025

    

September 30, 2024

    

September 30, 2025

    

September 30, 2024

(In thousands)

Barzolvolimab/Anti-KIT Program

$

51,619

$

34,393

$

133,967

$

88,643

CDX-622

 

5,617

 

3,628

 

14,906

 

10,175

Other Programs (a)

 

5,695

 

7,242

 

20,868

 

17,793

Total R&D Expense

$

62,931

$

45,263

$

169,741

$

116,611

(a)Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.

Three Months Ended

Three Months Ended

Nine Months Ended

Nine Months Ended

    

September 30, 2025

    

September 30, 2024

    

September 30, 2025

    

September 30, 2024

 

(In thousands)

Personnel

$

14,455

$

13,855

$

42,184

$

37,176

Laboratory supplies

 

1,057

 

1,074

 

4,769

 

3,997

Facility

 

1,410

 

1,263

 

4,214

 

3,799

Product development (b)

 

42,371

 

26,539

 

108,073

 

64,732

Other expenses (c)

 

3,638

 

2,532

 

10,501

 

6,907

Total R&D expense

$

62,931

$

45,263

$

169,741

$

116,611

(b)

Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.

(c)

Other expenses primarily include research and development consulting, insurance, licensing and software expenses.